Trials / Recruiting
RecruitingNCT07311564
A Study of LAD603 in Adults With Alopecia Areata
A Phase 2, Randomized, Placebo-controlled, Double-blind Clinical Study to Evaluate Efficacy and Safety of LAD603 in Adult Subjects With Severe to Very Severe Alopecia Areata
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 136 (estimated)
- Sponsor
- Almirall, S.A. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The main aim of the study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA). The study will also evaluate the safety, pharmacokinetics (PK), immunogenicity and pharmacodynamic (PD) biomarkers of LAD603.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LAD603 | LAD603 administered subcutaneously. |
| OTHER | Placebo | LAD603 matching placebo administered subcutaneously. |
Timeline
- Start date
- 2025-12-17
- Primary completion
- 2027-05-23
- Completion
- 2027-11-21
- First posted
- 2025-12-31
- Last updated
- 2026-01-12
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07311564. Inclusion in this directory is not an endorsement.